Search

The article reports that a pilot study found an experimental CBD cream to be effective in decreasing UVA-induced skin damage. Topics include the protective effects of CBD cream against UVA radiation, the study's methodology involving a small sample size and the use of nano-encapsulated CBD, and the potential implications for future dermatologic treatments.

The article highlights recent findings that GLP-1 receptor agonists (GLP-1RAs), commonly used for weight loss and diabetes management, may reduce the risk of several obesity-related cancers. Topics include: the observed lower cancer risk in diabetes patients using GLP-1RAs compared to those on insulin therapy, the specific types of obesity-related cancers with reduced risk, and the lack of evidence for decreased cancer risk with GLP-1RAs compared to metformin.

The article explores the continued reliance on fax machines in oncology despite advances in medical technology. Topics include: the contrast between cutting-edge medical innovations and outdated fax technology, the persistence of fax machines in healthcare for exchanging records, and the reasons for their continued use, such as inertia and resource limitations.

The article reveals that lifetime skin cancer prevalence among sexual minority (SM) Americans differs by race, ethnicity, and sexual identity compared to heterosexual peers, necessitating tailored prevention and screening efforts. Topics include: the identification of high-risk subgroups within the SM community, the use of data from the Behavioral Risk Factor Surveillance System for analysis, and the comparison of skin cancer prevalence among different racial and ethnic groups.

The article discusses the findings of a new analysis revealing that patients with treatment-refractory cancers who received eligibility waivers for a pan-cancer clinical trial had similar outcomes to those who met the original criteria. Topics include: the benefits of broadening eligibility criteria in clinical trials, the real-world applicability of trial results, and the ongoing debate about the impact of increased trial inclusivity on treatment safety and efficacy.

The article highlights Dr. Arisa E. Ortiz's priorities as the newly appointed president of the American Society for Laser Medicine and Surgery (ASLMS), emphasizing safety standards in laser medicine. Topics include Dr. Ortiz's extensive medical training and roles, her focus on innovations and safety in cutaneous surgery, and her achievements and awards in the field of dermatology.

The article reports that a recent global survey found that three-quarters of oncologists failed to identify various situations as conflicts of interest. Topics include the limited awareness and training on conflicts of interest in low-income countries, the ONCOTRUST-1 survey's findings on oncologists' perceptions of conflicts of interest, and the influence of industry payments on physicians in the U.S.

The article highlights the condition known as dermatoporosis, which is characterized by chronic skin fragility due to aging and sun damage. Topics include the identification and clinical management of dermatoporosis, the case study of a patient treated with topical and oral therapies leading to significant skin improvement, and the underlying pathophysiology involving decreased glycosaminoglycans and increased matrix metalloproteinases.

The article reports that dermatofibrosarcoma protuberans (DFSP) is twice as common in Black individuals compared to White individuals. Topics include the association between larger tumor size and older age with survival outcomes, the use of the National Cancer Institute's SEER registry to analyze DFSP incidence and outcomes, and factors linked to metastatic progression and overall survival.

The article reports that results from the latest survey by the National Comprehensive Cancer Network (NCCN) showed that numerous critical systemic anticancer therapies, primarily generic drugs, are currently in shortage. Topics include the widespread shortage of at least one drug at nearly 90% of responding NCCN member centers, the significant improvement in carboplatin and cisplatin shortages since 2023, and the ongoing issue of shortages affecting various chemotherapies.

The article focuses on reconsidering the approach to managing skin cancer in older patients, particularly questioning the universal use of surgery regardless of life expectancy, as highlighted by doctor Vishal A. Patel at a conference. Topics include the ongoing debate surrounding the appropriateness of surgery in older adults with limited life expectancy, the rising incidence of nonmelanoma skin cancers (NMSCs) in the elderly.

The article focuses on the incorporation of iron oxide into mineral sunscreens to enhance photoprotection, particularly in individuals with darker skin tones. Topics include the mechanism by which iron oxide blocks visible light, its effectiveness in reducing hyperpigmentation, and considerations for formulation and concentration in sunscreen products to optimize its benefits for diverse skin types.

The article focuses on the challenges faced by independent community oncology practices amidst increasing mergers and acquisitions by hospitals. Topics include the pressures on practices like Alliance Cancer Specialists to sell to hospitals, the strategies hospitals use to integrate vertically and control referrals, and efforts by practices to remain autonomous despite these pressures.

The article focuses on a pivotal experience that reshaped doctor Richard Leiter's understanding of hope in palliative care, recounted during an ASCO Voices session. Topics include the impact of a patient's mother challenging doctor Leiter's assumptions about hope, insights from other oncologists on the neurobiological and clinical significance of hope in patient care, and strategies for healthcare providers to address and support patient hopes effectively.

The article focuses on neurofilament light chain (Nfl) as a potential biomarker for detecting chemotherapy-induced peripheral neurotoxicity (CIPN). Topics include how Nfl levels increase after paclitaxel infusion and correlate with neuropathy severity months later, suggesting its utility in early detection of neurotoxicity.

The article focuses on the characteristics of Merkel cell carcinoma (MCC) in Hispanic patients compared to White patients, highlighting differences in age distribution, gender prevalence, and primary site of cancer manifestation. It mentions these findings were derived from a retrospective analysis of national cancer data presented at the Society for Investigative Dermatology meeting.

The article focuses on the FDA's accelerated approval of repotrectinib (Augtyro, Bristol Myers Squibb) for treating all advanced solid tumors with NTRK gene fusions that have progressed after initial treatment or lack alternative therapies. Topics include the expansion of repotrectinib's indication beyond ROS1-positive non-small cell lung cancer, its efficacy in treating rare NTRK gene fusions across various cancer types.

The article focuses on a study revealing that nearly one-third of physicians endorsing drugs and devices on the social media platform X did not disclose receiving payments from manufacturers, as required by professional guidelines. Topics include the investigation led by doctor Aaron Mitchell into physician compliance with disclosure rules, analysis of posts suggesting endorsements.

The article focuses on a large-scale French study published in JAMA Network Open, examining whether children conceived through assisted reproductive technology (ART) have a higher risk of cancer compared to naturally conceived children. Topics include the study's findings that, overall, children born through ART did not show an increased risk for cancer, but there was a slight elevation in leukemia risk among those conceived via IVF or ICSI.

The article explores the effectiveness of immersive virtual reality (VR) distraction therapy in managing pain among hospitalized patients with cancer, suggesting that VR therapy may offer greater and longer-lasting pain relief compared to two-dimensional guided imagery experiences. It underscores the potential of VR interventions in alleviating cancer-related pain and highlights the need for further research to optimize VR therapy in clinical settings.

The article examines healthcare providers' perspectives on prescribing opioids for chronic cancer pain, highlighting the complexity and lack of clear guidance in survivorship care. It mentions that based on qualitative interviews with providers from various specialties, the research underscores the need for evidence-based protocols and interdisciplinary communication to address the challenges in pain management for cancer survivors.

The article discusses the real-world effectiveness of repeat multicancer early detection (MCED) testing using the Galleri blood test, presented by Ora Karp Gordon, Doctor of Medicine, at the American Association for Cancer Research annual meeting. It states that the study indicates promising results in detecting early-stage and unscreened cancers through repeat testing, highlighting a shift towards earlier stage and unscreened cancer types.

The article discusses the ethical concerns raised by U.S. oncologists regarding the integration of artificial intelligence (AI) into cancer care decision-making, highlighting contradictory views on patient understanding and responsibility for AI biases. It presents findings from a recent survey showing that while most oncologists support patient consent and the ability to explain AI models.

The article focuses on the potential of new multicancer early detection (MCED) tests to identify cancers lacking routine screening options, as discussed at the American Association for Cancer Research annual meeting. It mentions that early data from tests like CanScan, MERCURY, and OncoSeek show promise in detecting various cancers with high accuracy, addressing a critical need, especially for cancers without established screening strategies.

The article delves into an analysis revealing that a significant portion of molecular-targeted cancer drugs approved in the United States lack substantial clinical benefits, with less than one-third demonstrating such benefits at the time of approval. It mentions that the study, led by Ariadna Tibau, Doctor of Medicine, from Brigham and Women's Hospital and Harvard Medical School, Boston, utilized frameworks to evaluate both the molecular targets and the clinical benefits of these drugs.

The article examines the effectiveness of cancer drugs approved under the US FDA's accelerated approval pathway, revealing that less than half of them have demonstrated improved overall survival or quality of life despite being on the market for over five years. It underscores the limitations of relying solely on surrogate markers for drug approvals and emphasizes the need for robust confirmatory trials to ensure real-world clinical benefits for patients.

The article explores the association between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors and the development of keratoacanthoma and cutaneous squamous cell carcinoma (cSCC), based on adverse event reports to the U.S. Food and Drug Administration (FDA). It states that analysis suggests relatively rare occurrences of keratoacanthoma and cSCC with PD-1/PD-L1 inhibitors, with signals detected in adverse event reports.

The article discusses a survey-based study revealing that only a small percentage of cancer survivors adhere to all four American Cancer Society (ACS) nutrition and physical activity guidelines, suggesting a gap between guidelines and behavior. It study emphasizes the importance of improving counseling on healthy behaviors for this vulnerable patient population.

The article discusses the risks of skin cancer and infections faced by solid organ transplant recipients due to their suppressed immune systems, emphasizing the importance of dermatologists being aware of these risks, as presented by Sean Christensen, at the American Academy of Dermatology's annual meeting. It underscores the risk of skin cancer associated with various immunosuppressive drugs and highlights the utility of a validated skin cancer risk assessment tool for transplant patients.

The article focuses on the use of circulating tumor DNA (ctDNA) to predict early treatment response in patients with HER2-positive cancers, highlighting its potential as a valuable tool in guiding treatment decisions and improving patient outcomes. It suggests that monitoring ctDNA dynamics can provide clinicians with important prognostic information, aiding in the assessment of response to targeted therapies.